Print this page
-
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma